Table 1.
Correlation between the maturation of TLS and clinico-pathological features in EBV-positive gastric cancer in the SYSUCC cohort.
| Characteristics | Available number | Tumor center | Tumor margin | |||||
|---|---|---|---|---|---|---|---|---|
| Non-mature TLSs | Mature TLSs | P valuea | Non-mature TMTLSs | Mature TMTLSs | P valuea | |||
| Gender | 148 | 0.624 | 0.969 | |||||
| Male | 131 (88.5%) | 46 (35.1%) | 85 (64.9%) | 61 (46.6%) | 70 (53.4%) | |||
| Female | 17 (11.5%) | 7 (41.2%) | 10 (58.8%) | 8 (47.1%) | 9 (52.9%) | |||
| Age (years) | 148 | 0.607 | 0.869 | |||||
| ≤ 57.0b | 74 (50.0%) | 28 (37.8%) | 46 (62.2%) | 34 (45.9%) | 40 (54.1%) | |||
| > 57.0 | 74 (50.0%) | 25 (33.8%) | 49 (66.2%) | 35 (47.3%) | 39 (52.7%) | |||
| Tumor size(cm) | 148 | < 0.001 | 0.005 | |||||
| ≤ 4.75c | 74 (50.0%) | 14 (18.9%) | 60 (81.1%) | 26 (35.1%) | 48 (64.9%) | |||
| >4.75 | 74 (50.0%) | 39 (52.7%) | 35 (47.3%) | 43 (58.1%) | 31 (41.9%) | |||
| Lauren type | 145 | 0.302 | 0.643 | |||||
| Intestinal | 43 (29.7%) | 11 (25.6%) | 32 (74.4%) | 17 (39.5%) | 26 (60.5%) | |||
| Diffuse | 21 (14.5%) | 9 (42.9%) | 12 (57.1%) | 10 (47.6%) | 11 (52.4%) | |||
| Mixed | 81 (55.8%) | 30 (37.0%) | 51 (63.0%) | 39 (48.1%) | 42 (51.9%) | |||
| T stage | 143 | < 0.001 | 0.003 | |||||
| T1+T2 | 40 (28.0%) | 2 (5.0%) | 38 (95.0%) | 10 (25.0%) | 30 (75.0%) | |||
| T3+T4 | 103 (72.0%) | 46 (44.7%) | 57 (55.3%) | 54 (52.4%) | 49 (47.6%) | |||
| N stage | 141 | 0.030 | 0.207 | |||||
| N0 | 37 (26.2%) | 7 (18.9%) | 30 (81.1%) | 13(35.1%) | 24 (64.9%) | |||
| N+ | 104 (73.8%) | 40 (38.5%) | 64 (61.5%) | 49 (47.1%) | 55 (52.9%) | |||
| M stage | 148 | < 0.001 | < 0.001 | |||||
| M0 | 125 (84.5%) | 33 (26.4%) | 92 (73.6%) | 48 (38.4%) | 77 (61.6%) | |||
| M1 | 23 (15.5%) | 20 (87.0%) | 3 (13.0%) | 21 (91.3%) | 2 (8.7%) | |||
| pTNM | 148 | < 0.001 | 0.001 | |||||
| I-II | 50 (33.8%) | 6 (12.0%) | 44 (88.0%) | 14 4 (28.0%) | 36 (72.0%) | |||
| III-IV | 98 (66.2%) | 47 (48.0%) | 51 (52.0%) | 55 (56.1%) | 43 (43.9%) | |||
| Vascular invasion | 142 | < 0.001 | 0.006 | |||||
| Absent | 68 (47.9%) | 11 (16.2%) | 57 (83.8%) | 22 (32.4%) | 46 (67.6%) | |||
| Present | 74 (52.1%) | 36 (48.6%) | 38 (51.4%) | 41 (55.4%) | 33 (44.6%) | |||
| Neural invasion | 142 | 0.013 | 0.306 | |||||
| Absent | 47 (33.1%) | 9 (19.1%) | 38 (80.9%) | 18 (38.3%) | 29 (61.7%) | |||
| Present | 95 (66.9%) | 38 (40.0%) | 57 (60.0%) | 45 (47.4%) | 50 (52.6%) | |||
| Differentiation | 140 | 0.068 | 0.078 | |||||
| Poorly | 83 (59.3%) | 35 (42.2%) | 48 (57.8%) | 44 (53.0%) | 39 (47.0%) | |||
| Moderately | 65 (46.4%) | 18 (27.7%) | 47 (72.3%) | 25 (38.5%) | 40 (61.5%) | |||
| PD-L1 expression | 148 | 0.090 | 0.435 | |||||
| CPS < 1 | 70 (47.3%) | 30 (42.9%) | 40 (57.1%) | 35 (50.0%) | 35 (50.0%) | |||
| CPS ≥ 1 | 78 (52.7%)) | 23 (29.5%) | 55 (70.5%) | 34 (43.6%) | 55 (56.4%) | |||
| Recurrence | 124 | < 0.001 | < 0.001 | |||||
| Yes | 30 (24.2%) | 21 (70.0%) | 9 (30.0%) | 20 (66.7%) | 10 (33.3%) | |||
| No | 94 (75.8%) | 14 (14.9%) | 80 (85.1%) | 29 (30.9%) | 65 (69.1%) | |||
| EBV-DNA | 64 | 0.557 | 0.420 | |||||
| Pos | 13 (21.5%) | 6 (46.2%) | 7 (53.8%) | 5 (38.5%) | 8 (61.5%) | |||
| Neg | 51 (78.5%) | 19 (37.3%) | 32 (62.7%) | 26 (51.0%) | 25 (49.0%) | |||
aChi-square test; bMedian age; cMedian size. TLS, tertiary lymphoid structure; EBV, Epstein-Barr virus; PD-L1, programmed death-ligand 1; CPS, the combined positive score.